IQVIA Holdings Inc. (NYSE:IQV) is one of the S&P 500 stocks that Jim Cramer shared his take on. Cramer called it a “great business,” as he said: Finally, the ninth-worst performing stock in the S&P 500 was IQVIA, down 22.3%. Now, this is a CRO, a contract research organization. Pharmaceutical companies hire these guys to run their clinical trials. Oh, what a great business. The CROs were all caught up in the AI displacement trade, unfairly, in my opinion. I just don’t see that happening at all. When IQVIA ...

白皮书 把握时机：生物科技的自我商业化黄金机会 跳过传统模型，实现以技术为中心的精益商业化的承诺 マークス・ゴーレス ，副总裁，思想领袖，艾昆纬 托马斯·贝克 高级副总裁，全球数据、技术和咨询服务，艾昆纬 查尔斯·林克 资深总监，信息管理与分析技术，IQVIA Mike Sanvoisin , 副总裁，生物技术商业服务，IQVIA 11 全方位合作伙伴外包服务 13 IQVIA能力：支持EBP自主商业化之旅 16 关于作者 18 执行摘要 医疗体系正越来越多地由懂得数字化决策者领导，他们期待更快速、更相关和个性化的信息 。随着代理型人工智能和使能技术的兴起，这一信息需求的变化正在颠覆传统的药品市场模 型，从根本上改写了商业化规则。 对于新兴生物医药公司（EBPs）来说，这创造了通过自我商业化 最大化其资产价值的独特机会。不受遗留商业基础设施的拖累，E BPs可以跳跃到一种精简的技术驱动商业模式，这种模式凭借量身 定制的功能，适合未来，能够实现规模化的快速、敏捷和精准参与 。 目录 执行摘要 1 引言 2 商业化新时代 3 生态商业模式（EBP）的黄金机遇：超越传统模式 6 奠定新模式的基石 7 现代数据管理： ...

IQVIA Holdings Inc. (NYSE:IQV) is one of the most undervalued AI stocks to buy now. With significant analyst and hedge fund sentiment, alongside a low forward price-to-earnings (PE) ratio, IQVIA Holdings Inc. (NYSE:IQV) secures a spot on our list of the most undervalued AI stocks to buy now. Following the company’s fourth-quarter earnings release, analysts at Mizuho and Truist revise their valuation models on IQVIA Holdings Inc. (NYSE:IQV). Incorporating the company’s Q4 performance, Mizuho lowered its ...

Investment Rating - The report emphasizes the importance of integrating electronic clinical outcome assessments (eCOAs) into oncology trials to meet regulatory guidelines and payer expectations, while minimizing patient burden [5]. Core Insights - The report highlights a shift towards patient-centered drug development in oncology, driven by regulatory initiatives such as the FDA's Project Optimus, which emphasizes the need for capturing patient experiences alongside traditional clinical outcomes [4][11]. - It identifies five key aspects of patient experience that should be measured in oncology trials, including disease-related symptoms, adverse events, overall impact of side effects, physical functioning, and role functioning [16][19]. - The report advocates for the use of eCOAs to enhance data collection efficiency and patient engagement, suggesting strategies such as using familiar devices, providing context for assessments, and ensuring ease of use [26][27][25]. Summary by Sections Patient Experience - Patient feedback is crucial for understanding the impact of treatments on their lives, and it adds significant value to drug development and evaluation [7]. - The FDA encourages the inclusion of appropriate clinical outcome assessments (COAs) to capture key patient experience elements, which are essential for regulatory submissions [11]. eCOA Strategies and Best Practices - The report outlines several recommendations for implementing eCOA strategies effectively, including: - Starting with a scientifically sound COA strategy to ensure relevant and efficient data collection [23]. - Considering decentralized clinical trials to reduce patient burden and enhance compliance [22]. - Allowing patients to use their own devices (BYOD) to facilitate participation and improve data collection rates [26]. - Providing patients with context about how their contributions to eCOAs benefit research, reinforcing the value of their participation [27]. Data Collection and Regulatory Compliance - The report stresses the importance of minimizing patient burden in data collection, suggesting that assessments should be relevant and not overly frequent [12][13]. - It emphasizes that the choice of assessment tools should align with regulatory expectations and capture valuable insights while respecting patients' time and energy constraints [18][19].

マークス・ゴーレス ，副总裁，思想领袖，艾昆纬 托马斯·贝克 高级副总裁，全球数据、技术和咨询服务，艾昆纬 查尔斯·林克 资深总监，信息管理与分析技术，IQVIA Mike Sanvoisin , 副总裁，生物技术商业服务，IQVIA 目录 执行摘要 1 引言 白皮书 把握时机：生物科技的自我商业化黄金机会 跳过传统模型，实现以技术为中心的精益商业化的承诺 2 商业化新时代 3 生态商业模式（EBP）的黄金机遇：超越传统模式 6 奠定新模式的基石 7 现代数据管理：技术赋能的EBP 8的核心基础 构想数据赋能的EBP商业引擎 9走向技术赋能的商业模型之路 11 全方位合作伙伴外包服务 13 IQVIA能力：支持EBP自主商业化之旅 16 关于作者 18 执行摘要 医疗体系正越来越多地由懂得数字化决策者领导，他们期待更快速、更相关和个性化的信息 。随着代理型人工智能和使能技术的兴起，这一信息需求的变化正在颠覆传统的药品市场模 型，从根本上改写了商业化规则。 对于新兴生物医药公司（EBPs）来说，这创造了通过自我商业化 最大化其资产价值的独特机会。不受遗留商业基础设施的拖累，E BPs可以跳跃到一种精简的技术驱动 ...

Core Insights - The article discusses IQVIA Holdings Inc.'s recent performance, highlighting a revenue of $4.017 billion in Q2, which was driven by growth in the Technology & Analytics Solutions (TAS) segment [1]. Company Performance - IQVIA reported a revenue of $4.017 billion in Q2, indicating a strong performance compared to previous quarters [1]. - The growth in revenue is primarily attributed to the Technology & Analytics Solutions (TAS) segment, suggesting a focus on innovative solutions within the healthcare sector [1]. Investment Focus - The article emphasizes the importance of innovative companies in the biotech and pharmaceutical sectors, particularly those developing breakthrough therapies with potential acquisition catalysts [1].

IQVIA Holdings Inc. (NYSE:IQV) is one of the best strong buy healthcare stocks to invest in. Mizuho cut the price target on IQVIA Holdings Inc. (NYSE:IQV) to $215 from $266 on February 23, reiterating an Outperform rating on the shares and updating its model on the company after the fiscal Q4 report. Truist also lowered the price target on the stock to $245 from $290 on February 19. It maintained a Buy rating on the shares, telling investors that it is updating its model on IQVIA Holdings Inc. (NYSE:IQV) a ...

Core Insights - The discussion focuses on the performance of the TAS segment, highlighting a 7% growth in constant currency for the fourth quarter [2]. Group 1: Company Performance - The TAS segment experienced a notable growth of 7% in constant currency during the fourth quarter [2]. - Consulting services are emphasized as a key area of focus, particularly in relation to AI initiatives [2].

IQVIA (NYSE:IQV) 2026 Conference February 26, 2026 11:00 AM ET Company ParticipantsMike Fedock - Incoming CFORon Bruehlman - Outgoing CFOConference Call ParticipantsPatrick Donnelly - Managing Director, Tools and Diagnostics/CRO AnalystPatrick DonnellyI think we can look to get started. Thank you, everybody, for joining us, we're here at the Citi MedTech Access Day. I'm Patrick Donnelly, the tools and diagnostics CROs analyst here. Happy to have a unique opportunity here with Ron and Mike, incoming CFO, out ...

Broyhill Asset Management, an investment advisor, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. 2025 witnessed extreme market concentration and a strong focus on artificial intelligence, leaving many sectors behind. The Portfolio, which has been significantly reshaped, now trades at a substantial discount relative to the broader market. The firm strongly believes it will benefit as market fundamentals improve. For the year, the portfolio declined by 1.4%, un ...